Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Conbercept

Home DrugsConbercept

Investigational

Biotech

Conbercept

Unknown Manufacturer

Conbercept has been investigated for the basic science of Age-related Macular Degeneration.

Generate AI report

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Overview

Conbercept has been investigated for the basic science of Age-related Macular Degeneration.

Indications

用于治疗湿性年龄相关性黄斑变性(AMD)。

Technical identifiers

CAS Number: 1227158-72-6
UNII ID: 1P05PW62F3

Patents

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

ADENO-ASSOCIATED VIRUS VECTOR PLATFORM FOR DELIVERY OF KH902 (CONBERCEPT) AND USES THEREOF
Applicant: UNIV MASSACHUSETTSPriority: 2020
US